Elevance Health, Inc. ELV
Healthcare · Healthcare Plans · United States · S&P 500
Based on the available data, Elevance Health, Inc. gets an algorithmic score of 58/100. It trades at 392.73 $, with a bullish technical trend (RSI 41.8) and 34.9% annual volatility.
Updated: 2026-09-30
Open in the interactive tool →
Strengths
- Low beta (0.27): defensive profile.
Weaknesses
- Thin net margin (2.5%): vulnerable to costs.
Fundamentals
| P/E | 17.36 |
| Forward P/E | 13.30 |
| PEG | 1.30 |
| P/B | 1.90 |
| EV/EBITDA | 9.47 |
| P/S | 0.42 |
| ROE % | 11.13 |
| ROA % | 3.83 |
| Gross margin % | 25.99 |
| Operating margin % | 4.56 |
| Net margin % | 2.47 |
| Revenue growth % (y/y) | 1.40 |
| Earnings growth % (y/y) | -13.10 |
| Revenue CAGR % | 8.34 |
| Earnings CAGR % | -1.33 |
| Debt/Equity % | 68.95 |
| Current ratio | 1.52 |
| FCF yield % | 3.73 |
| Dividend yield % | 1.75 |
| Payout % | 30.34 |
Returns
| 1 month | 0.0 % |
| 3 months | +2.0 % |
| 6 months | +39.1 % |
| YTD | +12.5 % |
| 1 year | +25.7 % |
| 3 years | -7.6 % |
| 5 years | +11.5 % |
Risk
| 1-year volatility | 34.9 % |
| Beta | 0.27 |
| 5-year max drawdown | -50.4 % |
| Sharpe 1A | 0.72 |
Macroeconomic context
Defensive with structural growth (ageing population). Risks: drug-pricing regulation, patents and clinical trials. Low correlation with the cycle. As a US company, its valuation depends on the Fed, 10-year Treasury yields and the US earnings cycle.
How the score is calculated
The score combines profitability (ROE, ROA, net margin), growth (revenue and earnings), valuation (P/E, EV/EBITDA, free cash flow), financial strength (debt and liquidity; not applied to banks and insurers) and momentum (6 and 12-month returns and trend). It is an educational quantitative filter, not a buy or sell recommendation.